MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (Nasdaq: EXAS) today announced the initiation of the pivotal trial for the company’s multi-marker molecular diagnostic screening test for the early detection of colorectal cancer. The multi-center DeeP-C study (Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer) will generate data to support Exact Sciences’ planned PMA submission to the U.S. Food and Drug Administration (FDA). The company began enrolling patients in the study on June 30th, 2011. Exact Sciences is planning to have approximately 60 sites in the United States and Canada participate in the study. Those sites are expected to enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for colorectal cancer.
